Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice - Test2 - elhamkhani - TriplyDB

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

http://www.wikidata.org/entity/Q24629441

about

Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management A contemporary approach to body mass regulation mechanisms Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice Incretin mimetics as a novel therapeutic option for hepatic steatosis Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial Daily Eating Patterns and Their Impact on Health and Disease.Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Pathogenesis of non-alcoholic fatty liver disease.Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Modern approach to the clinical management of non-alcoholic fatty liver disease Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects.Translational approaches: from fatty liver to non-alcoholic steatohepatitis.Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition Exendin-4 Improves Nonalcoholic Fatty Liver Disease by Regulating Glucose Transporter 4 Expression in ob/ob Mice.Treatment options for nonalcoholic Fatty liver disease Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments.Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice Neonatal exendin-4 reduces growth, fat deposition and glucose tolerance during treatment in the intrauterine growth-restricted lamb.Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver.Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity.Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1.The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis.The role of metformin in the management of NAFLD Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function.Non-alcoholic fatty liver disease in 2015.

P2860

Q24647189-BF811A4B-75D7-418D-BA48-1B8D19CDD614 Q24649618-D66970D3-E75C-4979-B000-63609EE3257A Q26746835-601A3147-3B17-46A2-A352-D7AF25438CDD Q26800894-6915C7C4-9CB4-4BD2-B8D5-CE72F51FB5D1 Q26827183-1FEADE56-DE86-44D8-AAE0-77A706BE612D Q27025423-CEE4274C-A0DA-4E17-880A-9EE539AE50F9 Q27027920-70563B45-E93E-4029-911F-EF5B39AD25D8 Q27316004-25925E54-C83F-4D18-915F-7768B963FF38 Q28261998-5BA6156E-D3E1-4D2F-B924-C9689C3757FB Q28661700-C142B607-DBB6-4C40-BD17-1FF7D1941F02 Q30382902-FE5BAB26-4C7C-465B-BB7D-765BCA363C71 Q30577903-1C1397E1-3530-47DE-B437-E09566266231 Q31149434-B4FC4271-D1F6-4738-82EF-5013B2010F29 Q33358112-76690821-52C9-43BD-A385-A4DDE8341695 Q33603384-06215620-85FA-4303-B02C-001662477394 Q33606303-214DC552-4C8D-442C-AC9D-E6C0C33CA831 Q33607697-90A4BFC0-54C4-43D0-AF11-D5F87587D888 Q33802278-7EAE3F39-B2F9-4108-80FE-758324159EAF Q33886923-1B3E92CC-EE6E-4BFC-AFA1-91E0EC6813B7 Q33927198-067824BE-88A5-45C1-A0DE-6605E843610C Q33958697-5E7FFF15-E7B7-4B05-8D66-FAB46A87E7BC Q33970970-BBA9927A-FAF9-4602-BBBC-95D05B2E1894 Q34015968-F6D44238-A0C3-4F3E-9E48-AE86F54120D5 Q34097903-C241475B-E2FE-4DA5-938D-F4CFA387A2B0 Q34156317-A9BE9200-357F-4483-B1D6-762C1D1462B8 Q34170885-996CD26E-7B76-4F68-A833-C95309B7EEBD Q34405101-CD8937FC-32FA-4EB6-A458-ED5CEF27D98D Q34406806-11568A57-00F8-4706-BD10-57197DC47139 Q34449857-A6D8E867-9215-40B1-88CE-032847C78722 Q34469947-4F834AFE-CE5F-4FCC-9F35-4FC540A7EACC Q34592864-BDD7CD7E-0EB1-40F5-B32C-63A74829E721 Q34627493-FF8D03E1-D262-4CFD-B89A-B27E65384523 Q34718822-77F7F3A6-8A85-450C-BC7B-5649DE55A52A Q34733928-DF7C8B8D-C995-4352-82BA-1778EB515154 Q35047406-0F4DEBBA-A2D5-4552-80F9-B531401E4BA6 Q35090416-08E40D15-153E-4AEB-8888-0C09FC0B256F Q35599917-5191F50B-8541-4388-90CE-CCFD3B9AF2B8 Q35614956-8D8F5217-467E-4E65-A82F-963AFC58FA01 Q35630861-837AF359-E7C2-437D-8B0A-691A472C0885 Q35715883-0ECC05A4-D9DD-4A6E-B247-39EDB77C8CA7

P2860

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

http://www.wikidata.org/entity/Q24629441

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Exendin-4, a glucagon-like pro ...... epatic steatosis in ob/ob mice

@ast

Exendin-4, a glucagon-like pro ...... epatic steatosis in ob/ob mice

@en

Exendin-4, a glucagon-like pro ...... epatic steatosis in ob/ob mice

@nl

type

label

Exendin-4, a glucagon-like pro ...... epatic steatosis in ob/ob mice

@ast

Exendin-4, a glucagon-like pro ...... epatic steatosis in ob/ob mice

@en

Exendin-4, a glucagon-like pro ...... epatic steatosis in ob/ob mice

@nl

prefLabel

Exendin-4, a glucagon-like pro ...... epatic steatosis in ob/ob mice

@ast

Exendin-4, a glucagon-like pro ...... epatic steatosis in ob/ob mice

@en

Exendin-4, a glucagon-like pro ...... epatic steatosis in ob/ob mice

@nl

P1433

Q24629441-6511CC0B-04E5-4274-A175-D57FA128627F

P1476

Q24629441-50796852-908C-4DE9-90DE-E2FBCB35D9D7

P2093

Q24629441-448AE893-8026-491F-B68E-57B48AB357E9

Q24629441-72B75CEB-9D07-4A0B-BAD2-E6C054539CF4

Q24629441-90FB17D4-56E2-42A2-958C-0C9DF0A9B799

Q24629441-9544BCB7-090E-459C-BF7F-C932C3AF0D0E

Q24629441-C770D18A-0B79-47CF-8C31-DA9E94FE28A6

Q24629441-E47E3300-27FF-4988-91AD-1EE31FE86D41

P2860

Q24629441-05E39574-A426-4CEC-8C0D-4F4A4C7BD7F5

Q24629441-10299FB1-4887-439C-A579-CEC782D5F4E5

Q24629441-1549F10D-A73F-4636-BA2C-1F60645FBCE1

Q24629441-1CC8AA7A-AACB-40CA-90AF-98F27673C4D4

Q24629441-1FABA221-C07F-4E43-94AA-705B7763BC14

Q24629441-294233CB-5723-4C48-B69D-4A544DE0B127

Q24629441-3380433D-D37C-4AE7-9314-4071B73043E9

Q24629441-33B46F81-EE28-44C8-B862-4B1F57375D24

Q24629441-35539658-4402-4B42-A634-12B92F570CA5

Q24629441-358A3B0B-CAB0-41B2-B8AB-94E515E77353

P304

Q24629441-2D2C549F-D73E-4F69-B6A6-B089E118D1F0

P31

Q24629441-0910775B-1A43-40BB-B740-AA4AB2031E29

P3181

Q24629441-048A9702-34A3-4014-A865-8D39E4D2BB53

P356

Q24629441-241188C4-5DE4-4BCA-85E9-B99E8EC6044D

P407

Q24629441-521E434B-78A8-4944-8693-1C9C71CF7B1D

P433

Q24629441-E686C8E9-D1B9-4E88-8D34-D08906B8635D

P478

Q24629441-B071E0FE-0279-41E7-B0D3-91939889287F

P577

Q24629441-CC215589-BEEB-4E35-9082-D818F15AEAF3

P5875

Q24629441-5F63C4F2-9315-46A9-8E07-95E9D5D9EE09

P698

Q24629441-7C593D6C-7F44-4281-A1A5-8ACB1A1D2754

P932

Q24629441-AF554D10-AE18-48D9-9DDA-1A7CA65C4933

P3181

P356

P1433

P1476

Exendin-4, a glucagon-like pro ...... epatic steatosis in ob/ob mice

@en

P2093

Frank A Anania

http://www.w3.org/2001/XMLSchema#string

Narita Gupta

http://www.w3.org/2001/XMLSchema#string

Neeraj K Saxena

http://www.w3.org/2001/XMLSchema#string

Nitika Arora Gupta

http://www.w3.org/2001/XMLSchema#string

Songbai Lin

http://www.w3.org/2001/XMLSchema#string

Xiaokun Ding

http://www.w3.org/2001/XMLSchema#string

P2860

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

A role for glucagon-like peptide-1 in the central regulation of feeding

Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (DP97)

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Interferon-gamma down-regulates adenosine 2b receptor-mediated signaling and short circuit current in the intestinal epithelia by inhibiting the expression of adenylate cyclase

Lipotoxicity of the pancreatic beta-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids

Steatohepatitis: a tale of two "hits"?

GIP biology and fat metabolism.

P304

173-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1485283

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/HEP.21006

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7396124

http://www.w3.org/2001/XMLSchema#string

P698

16374859

http://www.w3.org/2001/XMLSchema#string

P932

2925424

http://www.w3.org/2001/XMLSchema#string